MoonLake Immunotherapeutics · Conversion · Class A ordinary shares, par value $0.0001 per share

What does this filing report?

An SEC Form 4 filing for MoonLake Immunotherapeutics records a conversion involving Class A ordinary shares, par value $0.0001 per share on December 19, 2025. The reported quantity was 196,316. The filing date is December 22, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

On December 19, 2025, the Reporting Person exchanged 5,836 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 196,316 Class A ordinary shares of the Issuer. In connection with the exchange, 196,316 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2

The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3

10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4

(continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.